KRASG12C exhibits allele-specific biology in pancreatic cancer and targeting CD24 sensitizes KRASG12C-driven tumors to sotorasib treatment

被引：0

作者：

Wei, Yongkun

Liu, Minghui

Nguyen, Phuoc T.

Pan, Dean N.

Yao, Wantong

Ying, Haoqiang

机构：

来源：

CANCER RESEARCH | 2024年 / 84卷 / 02期

关键词：

D O I：

10.1158/1538-7445.PANCA2023-C097

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

C097

引用

页数：2

共 50 条

[41] KRASG12C Inhibitor as a Treatment Option for Non-Small-Cell Lung Cancer with Comorbid Interstitial Pneumonia [J].

Fujimoto, Kazushi ;

Ikeda, Satoshi ;

Tabata, Erina ;

Kaneko, Taichi ;

Sagawa, Shinobu ;

Yamada, Chieri ;

Kumagai, Kosumi ;

Fukushima, Takashi ;

Haga, Sanshiro ;

Watanabe, Masayuki ;

Muraoka, Tatsuya ;

Sekine, Akimasa ;

Baba, Tomohisa ;

Ogura, Takashi .

CANCERS, 2024, 16 (07)

[42] Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer [J].

Irati Macaya ;

Marta Roman ;

Connor Welch ;

Rodrigo Entrialgo-Cadierno ;

Marina Salmon ;

Alba Santos ;

Iker Feliu ;

Joanna Kovalski ;

Ines Lopez ;

Maria Rodriguez-Remirez ;

Sara Palomino-Echeverria ;

Shane M. Lonfgren ;

Macarena Ferrero ;

Silvia Calabuig ;

Iziar A. Ludwig ;

David Lara-Astiaso ;

Eloisa Jantus-Lewintre ;

Elizabeth Guruceaga ;

Shruthi Narayanan ;

Mariano Ponz-Sarvise ;

Antonio Pineda-Lucena ;

Fernando Lecanda ;

Davide Ruggero ;

Purvesh Khatri ;

Enrique Santamaria ;

Joaquin Fernandez-Irigoyen ;

Irene Ferrer ;

Luis Paz-Ares ;

Matthias Drosten ;

Mariano Barbacid ;

Ignacio Gil-Bazo ;

Silve Vicent .

Nature Communications, 14

[43] A phase 1b study evaluating the safety and efficacy of sotorasib, a KRASG12C inhibitor, in combination with trametinib, a MEK inhibitor, in KRAS p.G12C-Mutated Solid Tumors [J].

Ramalingam, Suresh ;

Fakih, Marwan ;

Strickler, John ;

Govindan, Ramaswamy ;

Li, Bob T. ;

Goldberg, Sarah ;

Gandara, David ;

Burns, Timothy ;

Barve, Minal ;

Shu, Catherine ;

Frank, Richard ;

Sohal, Davendra ;

Jafarinasabian, Pegah ;

Dai, Tian ;

Mather, Omar ;

Hong, David .

MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)

[44] Sotorasib-induced liver and non-liver toxicity associated with sequential sotorasib following anti-PD(L)1 in KRASG12C mutant lung cancer [J].

Chour, A. ;

Denis, J. ;

Lafitte, C. ;

Mascaux, C. ;

Zysman, M. ;

Lemaitre, A. ;

Swalduz, A. ;

Gounant, V. ;

Cortot, A. ;

Darrason, M. ;

Cadranel, J. ;

Auclin, E. ;

Basse, C. ;

Tissot, C. ;

Decroisette, C. ;

Bombaron, P. ;

Giroux-Leprieur, E. ;

Falchero, L. ;

Lebosse, F. ;

Duruisseaux, M. .

ANNALS OF ONCOLOGY, 2022, 33 :S49-S50

[45] Efficacy and toxicity of drugs targeting KRASG12C mutation in non-small cell lung cancer: a meta-analysis [J].

Luo, Wei ;

Zhu, Jing ;

Zhang, Wenxue ;

Yu, Airu ;

Zhou, Wei ;

Xu, Ke .

EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (12) :1295-1303

[46] NT219, a dual inhibitor of IRS1/2 and STAT3, suppresses cancer stem cell mediated resistance to KRASG12C and KRASG12D inhibitors in solid tumors [J].

Reuveni, Hadas ;

Al-Hallak, Mohammed Najeeb ;

Motorwala, Sarah ;

Beal, Eliza ;

Kim, Steve ;

Beydoun, Rafic ;

Dyson, Gergory ;

El-Rayes, Bassel ;

Chen, Herbert ;

Philip, A. Philip ;

Shields, Anthony F. ;

Pasche, Boris ;

Sigalov, Katy ;

Ben-David, Hava ;

Miron, Daphna ;

Azmi, Asfar S. .

CANCER RESEARCH, 2024, 84 (06)

[47] Comparison Between Sotorasib with Docetaxel for the Treatment of Chinese Patients with Previously Treated NSCLC with KRASG12C Mutation: A Cost-Effectiveness Analysis to Inform Drug Pricing [J].

Yi, Lidan ;

Zeng, Xiaohui ;

Zhou, Zhen ;

Liu, Qiao .

ADVANCES IN THERAPY, 2024, 41 (08) :3159-3172

[48] Cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRASG12C mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland [J].

El Saadany, T. ;

Lupatsch, J. ;

Mark, M. ;

Mehra, T. ;

Schwenkglenks, M. ;

von Moos, R. .

SWISS MEDICAL WEEKLY, 2023, 153 :56S-56S

[49] Trial in progress: Phase 1 study of BI 1823911, an irreversible KRASG12C inhibitor targeting KRAS in its GDP-loaded state, as monotherapy and in combination with the pan-KRAS SOS1 inhibitor BI 1701963 in solid tumors expressing KRASG12C mutation [J].

Waizenegger, Irene C. ;

Lu, Hengyu ;

Thamer, Claus ;

Savarese, Fabio ;

Gerlach, Daniel ;

Rudolph, Dorothea ;

Vellano, Christopher P. ;

Marotti, Marcelo ;

Heymach, John ;

Kopetz, Scott ;

Heffernan, Timothy P. ;

Marszalek, Joseph R. ;

Petronczki, Mark P. ;

Hofmann, Marco H. ;

Kraut, Norbert .

CANCER RESEARCH, 2022, 82 (12)

[50] Sotorasib versus docetaxel for previously treated non-small- cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial [J].

de Langen, Adrianus Johannes ;

Johnson, Melissa L. ;

Mazieres, Julien ;

Dingemans, Anne -Marie C. ;

Mountzios, Giannis ;

Pless, Miklos ;

Wolf, Jurgen ;

Schuler, Martin ;

Lena, Herve ;

Skoulidis, Ferdinandos ;

Yoneshima, Yasuto ;

Kim, Sang-We ;

Linardou, Helena ;

Novello, Silvia ;

van der Wekken, Anthonie J. ;

Chen, Yuanbin ;

Peters, Solange ;

Felip, Enriqueta ;

Solomon, Benjamin J. ;

Ramalingam, Suresh S. ;

Dooms, Christophe ;

Lindsay, Colin R. ;

Ferreira, Carlos Gil ;

Blais, Normand ;

Obiozor, Cynthia C. ;

Wang, Yang ;

Mehta, Bhakti ;

Varrieur, Tracy ;

Ngarmchamnanrith, Gataree ;

Stollenwerk, Bjorn ;

Waterhouse, David ;

Paz-Ares, Luis .

LANCET, 2023, 401 (10378) :733-746

← 1 2 3 4 5 →